Start with the building and the symptoms
Dampness and visible mold are associated with asthma, respiratory symptoms and allergic disease. Symptoms such as fatigue or brain fog are nonspecific and need a broader clinical evaluation rather than being attributed to mold from a checklist alone.
CIRS is used by some clinicians as a framework for persistent multisystem symptoms after water-damaged-building exposure, but it is not a widely established medical diagnosis and its biomarkers and treatment approach remain debated.
Symptoms that should make you suspect mold
- Symptoms that improve when you leave your home or office for 2+ weeks (vacation, travel)
- Sudden onset of multiple symptoms after moving into a new home
- Mast cell flares — flushing, hives, food sensitivities that keep multiplying
- Low testosterone or estrogen that doesn't respond to standard hormone protocols (read more)
- Persistent sinus inflammation, post-nasal drip, or chronic cough
- Brain fog, word-finding issues, executive dysfunction
- Family members or pets also unwell in the same building
Testing — and why one test isn't enough
- Urine mycotoxin panel (RealTime Labs, Vibrant Wellness, GPL-MycoTOX). Provoked or unprovoked — we pick based on clinical picture.
- Visual Contrast Sensitivity (VCS) — a fast screening proxy for neurotoxin load.
- HLA-DR genotyping — predicts ability to clear mycotoxins, drives prognosis and protocol intensity.
- Qualified moisture and mold inspection at home or work. The EPA does not recommend ERMI for routine consumer decisions because it was developed as a research tool.
- Clinical testing chosen for the symptoms and diagnoses under consideration; no single biomarker panel proves CIRS or that a building caused an illness.
How we treat it
- Remove exposure first. Non-negotiable. Remediate or relocate. No protocol overcomes ongoing exposure.
- Open drainage pathways — liver, kidney, lymph, bowel — before binders.
- Targeted binders — cholestyramine, charcoal, clay, chlorella — chosen per mycotoxin profile. Read our protocol guide for the binder hierarchy.
- Antifungals when colonization is present (sinus, gut).
- Immune & mast cell modulation — quercetin, DAO, low-dose naltrexone when indicated.
- Mitochondrial & hormone rebuild once burden is dropping.
- Nervous-system work — limbic retraining, vagal tone — to lock in resilience.
The binder hierarchy — which binder, for which mycotoxin, in what order
Binders are not interchangeable. Each one grabs a different family of mycotoxins, and giving the wrong one is why people take charcoal for a year and retest unchanged. Sequence matters more than dose: drainage first, then the binder matched to your urine panel, then a second binder layered in if the panel shows more than one family.
| Binder | Best for | Clinical notes |
|---|---|---|
| Cholestyramine (CSM) | Ochratoxin A, trichothecenes | Strongest evidence, prescription. Constipating — bowel must be moving daily first. |
| Welchol (colesevelam) | Same families, lower potency | Better tolerated when CSM causes reflux or GI shutdown. |
| Activated charcoal | Broad, non-specific | Also binds nutrients and medication — dose two hours away from everything. |
| Bentonite / zeolite clay | Aflatoxin, endotoxin | Useful in gut-driven cases and for die-off buffering. |
| Chlorella | Aflatoxin, metals | Gentle enough for sensitive patients and children; slow. |
| Saccharomyces boulardii | Ochratoxin, candida overgrowth | Doubles as antifungal support during the candida overlap below. |
Full dosing and stacking logic is in our mycotoxin binder comparison guide and the binders-and-drainage protocol. The Klinghardt metals protocol covers what changes when metals sit underneath the mold.
Candida and mold: the overlap almost nobody sequences correctly
Mycotoxins suppress the immune surveillance that keeps commensal yeast in check, so chronic mold exposure and candida overgrowth arrive together far more often than either arrives alone. Treat one and ignore the other and the patient plateaus: kill candida while mold burden is high and it returns within weeks; bind mycotoxins while the gut is fermenting and every binder dose triggers a flare.
- Signs both are running: sugar cravings that intensify on binders, white-coated tongue, recurrent vaginal or skin yeast, bloating within 20 minutes of eating, and die-off reactions far bigger than the dose justifies.
- How we test: organic acids (arabinose, tartaric acid) alongside the urine mycotoxin panel, plus stool culture when sinus or gut colonisation is suspected.
- The order we run it: drainage → gentle binder → antifungal (herbal, then prescription if colonisation is confirmed) → full-dose binder → gut rebuild. Antifungals before drainage is the classic error.
- Diet's real role: lowering fermentable sugars reduces symptom load but never clears colonisation on its own. It buys tolerance for the protocol, nothing more.
Colonisation in the sinuses behaves differently from gut yeast and needs topical antifungals as well as systemic — this is the pattern behind most "six years of chronic sinusitis" cases we take on.
ART — how we sequence when the labs disagree with the patient
Autonomic Response Testing (ART), the assessment method developed by Dr. Dietrich Klinghardt, is used by some practitioners as a sequencing framework. It is not an independently validated diagnostic test and should not determine whether a person has mold exposure or illness.
- How practitioners use it: as a hypothesis-generating tool when deciding what to discuss or investigate next.
- What it does not do: diagnose mold illness, quantify exposure or replace established environmental and medical evaluation.
- Where it changes the protocol: patients who crash on standard binder doses, cases stalled after months of "correct" treatment, and children who can't tolerate aggressive detox.
Read the full method in our ART explainer and the ART practice page, or see how it fits the wider framework on the Klinghardt protocol guide and the modern mold protocol update.
Why most mold programs stall
Three patterns dominate failed mold protocols:
- Binders without drainage. Cholestyramine without an open liver and bowel just recirculates toxins. Patients feel worse, blame the binder, quit.
- No environmental work. Treating the patient without testing the building is the single most expensive mistake in mold care. You're bailing while the leak runs.
- No nervous-system layer. Mold drives MCAS and limbic sensitization. If you don't address it, the body stays primed to react to everything — long after the mycotoxins are gone.
Our Foundation Membership sequences all of this; for patients with high HLA-DR-linked biotoxin sensitivity and heavy DNA stress load, the DNA Precision Program is usually required.
What healing actually looks like — months 1, 3, 6, 12
Month 1 — Environmental testing done, exposure removed or remediation plan in motion. Drainage open. Initial symptom relief.
Month 3 — Binders engaged at full dose. Mycotoxin levels start dropping on retest. Mast cell flares space out.
Month 6 — Major burden clear. Hormones often re-balance without direct intervention. Brain fog noticeably lighter.
Month 12 — Mitochondrial rebuild mature. Nervous system has been re-trained. Most patients are off most of the protocol, on maintenance.